Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtox' drugs-of-abuse device:

This article was originally published in Clinica

Executive Summary

Medtox Scientific's Sure-Screen drugs-of-abuse point-of-collection test (POCT) device that it believes provides significantly lower detection levels for eight commonly abused drugs, compared with other FDA-cleared POCT product. The Sure-Screen device is designed to provide lower detection levels for marijuana, opiates, cocaine, amphetamines, methadone, benzodiazepines, methamphetamines and MDMA-Ecstasy by an average of around 50% each. The St Paul, Minnesota company believes that much lower detection levels will be in demand in markets interested in "zero tolerance".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel